national stem-cell therapy logo

Insulin Independence: Is This the Future for Type 1 Diabetes Patients?

Help Spread The Word, Share Post:

The press release from the American Diabetes Association presents promising findings from an ongoing clinical trial of VX-880, a novel stem cell-derived islet cell therapy for individuals with type 1 diabetes (T1D). The study, presented at the 83rd Scientific Sessions of the American Diabetes Association, demonstrates the potential of this therapy as a future treatment option for T1D patients.

The trial involves adult T1D patients with impaired hypoglycemic awareness and severe hypoglycemia. All patients treated with VX-880 had undetectable insulin secretion and a history of recurrent severe hypoglycemic events (SHE) in the year prior to treatment.

Post-treatment, all six patients showed restored insulin secretion, improved glycemic control, improved time-in-range, reduction or elimination of exogenous insulin usage, and complete absence of SHEs in the post-Day 90 evaluation period.

Two patients treated with VX-880 for at least 12 months became insulin independent and showed significant improvements in their HbA1c levels. Three additional patients, each administered the full target dose of VX-880 as a single infusion, have had up to 90 days of follow-up and also have shown insulin production, reduction in HbA1c, improvements in time-in-range, and reductions in daily insulin usage.

VX-880 has been generally safe and well tolerated in all patients dosed to date, with a safety profile consistent with immunosuppressant therapy and cadaveric islet cell transplantation. The majority of adverse events were mild or moderate, and there were no serious adverse events related to VX-880 treatment.

The positive safety and efficacy data have led an independent data review committee to recommend moving to Part C of the trial, which allows for concurrent dosing of patients at the full target dose of VX-880. The VX-880 trial has expanded to additional sites that are active and enrolling in Norway, Switzerland, and the Netherlands.

*** All content on is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

*** Our website contains affiliate advertisements. We may receive a commission for purchases made through these ads at no additional cost to you.

Stay Connected

More Updates